Kingworld Medicines Group Ltd. (HK:1110)
:1110
Want to see HK:1110 full AI Analyst Report?
1110 Stock Chart & Stats
HK$0.53
>-HK$0.01(-1.12%)
At close: 4:00 PM EST
HK$0.53
>-HK$0.01(-1.12%)
Day’s Range― - ―
52-Week RangeHK$0.39 - HK$0.78
Previous CloseN/A
Volume780.00K
Average Volume (3M)1.11M
Market Cap
HK$248.66M
Enterprise ValueHK$383.06M
Total Cash (Recent Filing)HK$274.70M
Total Debt (Recent Filing)HK$434.05M
Price to Earnings (P/E)18.8
Beta0.24
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.87%
Share Statistics
EPS (TTM)0.02
Shares Outstanding622,499,940
10 Day Avg. Volume874,800
30 Day Avg. Volume1,111,766
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)0.44
Price to Sales (P/S)0.30
P/FCF Ratio4.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross Margin StabilityStable mid-to-high 20% gross margins indicate the core product economics and procurement/pricing structure remain intact. That durability supports long-term margin floor even if operating costs fluctuate, preserving intrinsic product profitability and enabling focus on recovering operating leverage.
Distribution-focused Business ModelA distribution-centric model selling to wholesalers, pharmacies, hospitals and retail channels yields recurring product sales, lower capital intensity, and diversified downstream demand. Structural healthcare needs make this revenue mix relatively stable over multi-quarter horizons.
Positive Operating Cash GenerationConsistent positive operating cash flow and decent cash conversion (FCF ~two-thirds of net income) provide a durable funding source for working capital, dividends or selective reinvestment. While volatile historically, ongoing positive cash generation underpins financial flexibility.
Bears Say
Revenue DeclineSustained top-line contraction across consecutive years reduces scale benefits and pressures per-unit absorption of fixed costs. If revenue declines persist, it will hinder margin recovery, limit reinvestment capacity, and make restoring growth more costly and time-consuming.
Net Margin CompressionA sharp fall to ~1.2% net margin cuts the operating buffer against shocks and reduces retained earnings for reinvestment. Narrow profitability restricts ability to rebuild working capital or invest in distribution/brand, increasing vulnerability to cyclical or competitive pressures.
Rising LeverageA materially higher debt-to-equity ratio increases fixed financing obligations and reduces financial flexibility. With cash flow volatility and compressed returns, higher leverage raises refinancing and liquidity risk and constrains the company's ability to fund growth or absorb setbacks.
Kingworld Medicines Group Ltd. News
1110 FAQ
What was Kingworld Medicines Group Ltd.’s price range in the past 12 months?
Kingworld Medicines Group Ltd. lowest stock price was HK$0.39 and its highest was HK$0.78 in the past 12 months.
What is Kingworld Medicines Group Ltd.’s market cap?
Kingworld Medicines Group Ltd.’s market cap is HK$248.66M.
When is Kingworld Medicines Group Ltd.’s upcoming earnings report date?
Kingworld Medicines Group Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 72 days.
How were Kingworld Medicines Group Ltd.’s earnings last quarter?
Kingworld Medicines Group Ltd. released its earnings results on Mar 31, 2026. The company reported HK$0.031 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.031.
Is Kingworld Medicines Group Ltd. overvalued?
According to Wall Street analysts Kingworld Medicines Group Ltd.’s price is currently Overvalued.
Does Kingworld Medicines Group Ltd. pay dividends?
Kingworld Medicines Group Ltd. pays a Annually dividend of HK$0.032 which represents an annual dividend yield of 5.87%. See more information on Kingworld Medicines Group Ltd. dividends here
What is Kingworld Medicines Group Ltd.’s EPS estimate?
Kingworld Medicines Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kingworld Medicines Group Ltd. have?
Kingworld Medicines Group Ltd. has 622,499,940 shares outstanding.
What happened to Kingworld Medicines Group Ltd.’s price movement after its last earnings report?
Kingworld Medicines Group Ltd. reported an EPS of HK$0.031 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Kingworld Medicines Group Ltd.?
Currently, no hedge funds are holding shares in HK:1110
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kingworld Medicines Group Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.19%
12-Months-Change
Fundamentals
Return on Equity
1.78%
Trailing 12-Months
Asset Growth
6.64%
Trailing 12-Months
Company Description
Kingworld Medicines Group Ltd.
Kingworld Medicines Group Limited functions as an investment holding company primarily engaged in the distribution of imported, branded pharmaceutical and healthcare items. The company also supplies a range of medical products, health goods, and general food items. Its extensive product catalog caters to various therapeutic areas, such as respiratory relief (for cough and phlegm), gastrointestinal issues, vitamin supplementation, orthopedic support, cardiovascular health, and influenza care. Key brands distributed include Nin Jiom Chuan Bei Pei Pa Koa, Taiko Seirogan, the Kawai Product Range, Flying Eagle Wood Lok Medicated Oil, Kyushin Pill, and the Mentholatum Product Range. Furthermore, Kingworld is involved in the production and sale of electrotherapeutic and physiotherapeutic devices, as well as common medical examination equipment. Its market presence spans the People's Republic of China, Hong Kong, the United States, the United Kingdom, Germany, Italy, Spain, Mexico, and other international regions. The company, founded in 1996, is headquartered in Shenzhen, PRC.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Tianda Pharmaceuticals Ltd.
―
Wai Yuen Tong Medicine Holdings Limited
―
PuraPharm Corp. Ltd.
―
Pak Fah Yeow International Limited
―